By leveraging the high binding affinity of the peptide nucleic acid (PNA) forms of siCEACAM6 and miR-29a, we developed a pHLIP-fused delivery system with tumor-specific targeting properties and explored the therapeutic potential of CEACAM6 inhibition via siCEACAM6 and miR-29a in a PDAC xenograft model. Here, CEACAM6 is linked to neoplasm.